Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01270945 · ClinicalTrials.gov registry record · Phase 2
Safety and Preliminary Efficacy Study of an Anti-inflammatory Therapeutic Antibody in Reducing Restenosis.
A Phase 2 study of Patients Undergoing Repeat Peripheral Artery Revascularization, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
- 8
- Study locations
NCT01270945: Completed Phase 2 study of Patients Undergoing Repeat Peripheral Artery Revascularization, sponsored by Janssen Research & Development.
NCT01270945 is a Phase 2 study of Patients Undergoing Repeat Peripheral Artery Revascularization that has completed, run by Janssen Research & Development. The registered enrollment target is 43 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). The trial reports 8 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01270945, a Phase 2 study of Patients Undergoing Repeat Peripheral Artery Revascularization, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to determine if CV-18C3 will reduce the rate of restenosis or the time to restenosis in patients undergoing repeat peripheral artery revascularization versus controls randomized to standard of care.
Primary Outcome
adverse events, vitals signs, physical examination results and clinical laboratory values
Conditions Studied
Interventions
- PROCEDURE Standard of Care
- DRUG CV-18C3
Study Locations (8)
Florida
- JFK Medical Center - Atlantis
- River City Clinical Research - Jacksonville
- Jacksonville Center for Clinical Research - Jacksonville
- Mediquest Research Group - Ocala
California
- Sutter Heart & Vascular Institute - Sacramento
Georgia
- John D. Archbold Memorial Hospital - Thomasville
Ohio
- Univeristy of Cincinnati University Hospital - Cincinnati
Texas
- Methodist Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2011-06-30 |
| Est. Completion | 2014-04-30 |
| Phase | Phase 2 |
What the finished NCT01270945 record still lists
NCT01270945 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Patients Undergoing Repeat Peripheral Artery Revascularization appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.
NCT01270945 lists 8 locations in 5 states (Florida, California, Georgia).
Frequently Asked Questions
What is clinical trial NCT01270945 about?
NCT01270945 is a clinical study titled "Safety and Preliminary Efficacy Study of an Anti-inflammatory Therapeutic Antibody in Reducing Restenosis.". The purpose of this study is to determine if CV-18C3 will reduce the rate of restenosis or the time to restenosis in patients undergoing repeat peripheral artery revascularization versus controls randomized to standard of care.
What is the current status of trial NCT01270945?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2011-06-30. Estimated completion is 2014-04-30.
What conditions does trial NCT01270945 study?
This clinical trial studies the following conditions: Patients Undergoing Repeat Peripheral Artery Revascularization.
What interventions are being tested in trial NCT01270945?
The interventions under investigation include: Standard of Care (PROCEDURE), CV-18C3 (DRUG).
Who is sponsoring clinical trial NCT01270945?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01270945 being conducted?
This trial has 8 study locations across California, Florida, Georgia, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01270945's enrollment target sits among peer trials
43 1332nd of 2000 higher than 662 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI